Trial Profile

A clinical trial of BR111 for injection

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BR 111 (Primary)
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions

Most Recent Events

20 Feb 2025 New trial record
10 Feb 2025 According to a BioRay Pharmaceutical media release, the National Medical Products Administration (NMPA) has accepted the clinical trial application for BR111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com